O-1918

O-1918 is a synthetic compound that was originally identified in the early 2000s. It is often associated with the cannabinoid system due to its ability to act as an antagonist for the GPR18 receptor, which is a target of interest in the field of pharmacology.

History

O-1918 was first identified in the early 2000s. It was initially thought to be an antagonist for the CB1 receptor and CB2 receptor, which are the primary targets of the cannabinoid system. However, subsequent research has shown that O-1918 does not have significant activity at these receptors. Instead, it has been found to act as an antagonist for the GPR18 receptor.

Pharmacology

The primary target of O-1918 is the GPR18 receptor. This receptor is a member of the G protein-coupled receptor family and is expressed in various tissues throughout the body, including the central nervous system and immune system. The exact role of GPR18 is still not fully understood, but it is thought to be involved in a variety of physiological processes, including inflammation, pain perception, and immune response.

O-1918 acts as an antagonist for the GPR18 receptor, meaning that it blocks the receptor's activity. This can potentially be used to modulate the receptor's effects, although the exact therapeutic potential of O-1918 is still under investigation.

Research and Potential Therapeutic Uses

Research into O-1918 and the GPR18 receptor is still in its early stages. However, due to the wide expression of GPR18 and its involvement in various physiological processes, there is significant interest in the potential therapeutic uses of O-1918.

Some potential areas of interest include the treatment of chronic pain, inflammatory diseases, and neurodegenerative diseases. However, more research is needed to fully understand the potential benefits and risks of O-1918.

See Also

• Cannabinoid
• G protein-coupled receptor
• Pharmacology

O-1918 Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.